2015
Efficacy of systemic adoptive transfer immunotherapy targeting NY-ESO-1 for glioblastoma
Everson R, Antonios J, Lisiero D, Soto H, Scharnweber R, Garrett M, Yong W, Li N, Li G, Kruse C, Liau L, Prins R. Efficacy of systemic adoptive transfer immunotherapy targeting NY-ESO-1 for glioblastoma. Neuro-Oncology 2015, 18: 368-378. PMID: 26330563, PMCID: PMC4767237, DOI: 10.1093/neuonc/nov153.Peer-Reviewed Original ResearchConceptsNY-ESO-1NY-ESO-1-specific T cellsCells treated with decitabineDiffusely infiltrating tumor cellsAdoptive T cell therapyIntracranial human glioma xenograftsT-cell therapyDemethylating agent decitabineTumor rejection antigensGlioma-bearing miceSignificant survival benefitSquamous cell carcinomaPhenotype of lymphocytesT cell traffickingInfiltrating tumor cellsIdeal treatment modalityReal-time cytotoxicity assayHuman glioma xenograftsHuman glioblastoma cell culturesLong-term survivalClinically feasible strategyLong-term survival of animalsIn vitro treatmentTreatment of glioblastomaGlioblastoma cell cultures
2013
Mammaglobin B (SCGB2A1) is a novel tumour antigen highly differentially expressed in all major histological types of ovarian cancer: implications for ovarian cancer immunotherapy
Bellone S, Tassi R, Betti M, English D, Cocco E, Gasparrini S, Bortolomai I, Black JD, Todeschini P, Romani C, Ravaggi A, Bignotti E, Bandiera E, Zanotti L, Pecorelli S, Ardighieri L, Falchetti M, Donzelli C, Siegel ER, Azodi M, Silasi DA, Ratner E, Schwartz PE, Rutherford TJ, Santin AD. Mammaglobin B (SCGB2A1) is a novel tumour antigen highly differentially expressed in all major histological types of ovarian cancer: implications for ovarian cancer immunotherapy. British Journal Of Cancer 2013, 109: 462-471. PMID: 23807163, PMCID: PMC3721400, DOI: 10.1038/bjc.2013.315.Peer-Reviewed Original ResearchConceptsCytotoxic T lymphocytesMajor histological typesOvarian cancerDendritic cellsHistological typeMammaglobin BType 1 cytokine profileMonocyte-derived dendritic cellsClass I monoclonal antibodiesTumor cellsMetastatic/recurrentOvarian cancer immunotherapyAutologous tumor cellsImmunotherapy of patientsIntracellular cytokine expressionNovel tumor antigensOvarian cancer typesTumor rejection antigensRecurrent diseaseCytokine profileCytokine expressionOvarian tumorsCancer immunotherapyCTL populationsOvarian carcinoma
2012
Repertoire Enhancement with Adoptively Transferred Female Lymphocytes Controls the Growth of Pre-Implanted Murine Prostate Cancer
Jenq R, Curran M, Goldberg G, Liu C, Allison J, van den Brink M. Repertoire Enhancement with Adoptively Transferred Female Lymphocytes Controls the Growth of Pre-Implanted Murine Prostate Cancer. PLOS ONE 2012, 7: e35222. PMID: 22493742, PMCID: PMC3320876, DOI: 10.1371/journal.pone.0035222.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAnimalsAntigens, NeoplasmCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesDEAD-box RNA HelicasesFemaleGraft vs Host DiseaseHumansImmunotherapy, AdoptiveLymphocyte CountMaleMiceMinor Histocompatibility AntigensNeoplasm TransplantationProstatic NeoplasmsSex FactorsWhole-Body IrradiationConceptsCD4 T cellsT cellsProstatic adenocarcinoma cellsAdoptive transferProstate cancerEffective anti-tumor immune responseCancer-reactive T cellsCD8 T cell responsesHigh-affinity T cellsPotential tumor rejection antigensTRAMP-C2 tumor cellsAnti-tumor immune responseAdenocarcinoma cellsExacerbation of graftPresence of CD25Female lymphocytesRegulatory T cellsAdoptive transfer modelReactive T cellsT cell responsesT cell repertoireMurine prostate cancerProstate cancer antigenAdult male hostsTumor rejection antigens
1998
Radiation‐enhanced expression of E6/E7 transforming oncogenes of human papillomavirus‐16 in human cervical carcinoma
Santin A, Hermonat P, Ravaggi A, Chiriva‐Internati M, Pecorelli S, Parham G. Radiation‐enhanced expression of E6/E7 transforming oncogenes of human papillomavirus‐16 in human cervical carcinoma. Cancer 1998, 83: 2346-2352. PMID: 9840534, DOI: 10.1002/(sici)1097-0142(19981201)83:11<2346::aid-cncr14>3.0.co;2-g.Peer-Reviewed Original ResearchConceptsE6/E7 oncoproteinsMHC class ICervical carcinoma cell linesCarcinoma cell linesCervical carcinomaDose-dependent mannerE6/E7High dosesE7 oncoproteinsSiHa cell lineClass IRadiation therapyMajor histocompatibility complex restriction elementCell linesRadiation-induced drug resistanceHigh-risk HPV genotypesHPV-positive cervical carcinoma cell linesTumor cellsE6/E7 oncogenesE7 oncoprotein expressionE7 viral proteinsHuman papillomavirus infectionImportant risk factorTumor rejection antigensHuman papillomavirus 16Effects of retinoic acid on the expression of a tumor rejection antigen (heat shock protein gp96) in human cervical cancer.
Santin AD, Hermonat PL, Ravaggi A, Chiriva-Internati M, Pecorelli S, Parham GP. Effects of retinoic acid on the expression of a tumor rejection antigen (heat shock protein gp96) in human cervical cancer. European Journal Of Gynaecological Oncology 1998, 19: 229-33. PMID: 9641219.Peer-Reviewed Original ResearchConceptsHeat shock protein gp96Shock protein gp96Tumor rejection antigensHuman cervical cancerCervical cancerRetinoic acidRejection antigensTumor cellsMajor histocompatibility complex class IPresentation of tumorHistocompatibility complex class IBiologic response modifiersCervical cancer cell linesCo-stimulation moleculesComplex class ICell linesCervical carcinoma cell linesHuman cervical carcinoma cell lineCancer cell linesCarcinoma cell linesHumoral immunityTherapeutic dosesViral antigensResponse modifiersICAM-1The effects of irradiation on the expression of a tumour rejection antigen (heat shock protein gp96) in human cervical cancer
Santin AD, Hermonat PL, Ravaggi A, Chiriva-Internati M, Hiserodt JC, Batchu RB, Pecorelli S, Parham GP. The effects of irradiation on the expression of a tumour rejection antigen (heat shock protein gp96) in human cervical cancer. International Journal Of Radiation Biology 1998, 73: 699-704. PMID: 9690688, DOI: 10.1080/095530098141951.Peer-Reviewed Original ResearchConceptsTumor rejection antigensHeat shock protein gp96Shock protein gp96Human cervical cancerCervical carcinoma cell linesRejection antigensHigh dosesHuman cervical carcinoma cell lineCervical cancerCarcinoma cell linesTumor cellsMajor histocompatibility complex class ILocal radiation therapyHistocompatibility complex class IBiologic response modifiersCo-stimulation moleculesComplex class ICell linesCervical cancer cellsDose-dependent mannerViral antigensResponse modifiersICAM-1Radiation therapyGp96 mRNA
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply